Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, announced the pricing of senior unsecured notes in an aggregate principal amount of US$3.5 billion, in an underwritten, registered public offering, consisting of US$750 million of 4.80% senior notes maturing in 2029, US$1 billion of 5.10% senior notes maturing in 2035, US$1 billion of 5.50% senior notes maturing in 2054, and US$750 million of 5.60% senior notes maturing in 2064. The offering closed on November 20, 2024.
Latham & Watkins LLP represented the underwriters in the offering with a corporate team led by New York/Los Angeles partner Greg Rodgers and Washington, D.C./New York partner Chuck Cassidy, with associates Karysa Norris and Steve Hess. Advice was also provided on tax matters by New York partner Bora Bozkurt; on healthcare matters by Bay Area partner Betty Pang; on intellectual property matters by San Diego/Bay Area partner Christopher Hazuka, with associates Robert Yeh and Patrick Chew; on data privacy matters by Heather Deixler, with associate Kiara Vaughn; on FDA regulatory matters by Washington, D.C. partner Ben Haas and Washington, D.C. counsel Chad Jennings, with associate Meryl Bartlett; on sanctions matters by Washington, D.C. counsel Ruchi Gill, with associate Elliot Hecht; on EU/UK regulatory matters by Paris/Brussels partner Eveline Van Keymeulen, with associate Jeanne Fabre; and on anti-corruption matters by Washington, D.C. partner Kevin Chambers.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
